380
Views
11
CrossRef citations to date
0
Altmetric
Methods Paper

Platelet aggregation impacts thrombin generation assessed by calibrated automated thrombography

, , , , &
Pages 156-161 | Received 29 Mar 2017, Accepted 04 Jul 2017, Published online: 12 Oct 2017

References

  • Cosemans JMEM, Angelillo-Scherrer A, Mattheij NJA, Heemskerk JWM. The effects of arterial flow on platelet activation, thrombus growth, and stabilization. Cardiovasc Res 2013;99(2):342–352.
  • Jackson SP. The growing complexity of platelet aggregation. Blood 2007;109(12):5087–5095.
  • Cosemans JMEM, Iserbyt BF, Deckmyn H, Heemskerk JWM. Multiple ways to switch platelet integrins on and off. J Thromb Haemost 2008;6(8):1253–1261.
  • Mazzucato M, Pradella P, Cozzi MR, De Marco L, Ruggeri ZM. Sequential cytoplasmic calcium signals in a 2-stage platelet activation process induced by the glycoprotein Ibalpha mechanoreceptor. Blood 2002;100(8):2793–2800.
  • Nesbitt WS, Kulkarni S, Giuliano S, Goncalves I, Dopheide SM, Yap CL, Harper IS, Salem HH, Jackson. Distinct glycoprotein Ib/V/IX and integrin alpha IIbbeta 3-dependent calcium signals cooperatively regulate platelet adhesion under flow. J Biol Chem 2002;277(4):2965–2972.
  • Farndale RW, Sixma JJ, Barnes MJ, de Groot PG. The role of collagen in thrombosis and hemostasis. J Thromb Haemost 2004;2(4):561–573.
  • Thiagarajan P, Tait JF. Collagen-induced exposure of anionic phospholipid in platelets and platelet-derived microparticles. J Biol Chem 1991;266(36):24302–24307.
  • Bevers EM, Comfurius P, Zwaal RF. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta 1983;736(1):57–66.
  • Zwaal RF, Comfurius P, van Deenen LL. Membrane asymmetry and blood coagulation. Nature 1977;268(5618):358–360.
  • van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 2008;142(6):889–903.
  • Adams M. Assessment of thrombin generation: useful or hype? Semin Thromb Hemost 2009;35(1):104–110.
  • Castoldi E, Duckers C, Radu C, Spiezia L, Rossetto V, Tagariello G, Rosing J, Simioni P. Homozygous F5 deep-intronic splicing mutation resulting in severe factor V deficiency and undetectable thrombin generation in platelet-rich plasma. J Thromb Haemost 2011;9(5):959–968.
  • Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Béguin S. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32 (5–6): 249–253.
  • Hemker HC. Thrombin generation: biochemical possibilities and clinical reality. Blood 2015;126(3):288–289.
  • Perrin J, Depasse F, Lecompte T, French-speaking CAT group and under the aegis of GEHT, French-speaking CAT group (all in France unless otherwise stated):, French-speaking CAT group all in France unless otherwise stated. Large external quality assessment survey on thrombin generation with CAT: further evidence for the usefulness of normalisation with an external reference plasma. Thromb Res 2015;136(1):125–130.
  • Samama MM, Le Flem L, Guinet C, Gerotziafas G, Depasse F. Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants. J Thromb Haemost 2007;5(12):2554–2566.
  • Cohen H, Doré CJ, Clawson S, Hunt BJ, Isenberg D, Khamashta M, Muirhead N, RAPS Trial Protocol Collaborators (2015). Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. Lupus 2015;24(10):1087–1094.
  • Douxfils J, Chatelain B, Chatelain C, Dogné J-M, Mullier F. Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide. Thromb Haemost 2016;115(2):368–381.
  • van Hylckama Vlieg A, Baglin CA, Luddington R, MacDonald S, Rosendaal FR, Baglin TP. The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study. J Thromb Haemost 2015;13(9):1642–52.
  • Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost 2008;6(8):1327–33.
  • Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 2008;6(10):1720–5.
  • Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006;296(4):397–402.
  • van Hylckama Vlieg A, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol 2007;138(6):769–74.
  • Mancuso ME, Chantarangkul V, Clerici M, Fasulo MR, Padovan L, Scalambrino E, Peyvandi F, Tripodi A, Santagostino. The thrombin generation assay distinguishes inhibitor from non-inhibitor patients with severe haemophilia A. Haemophilia 2016;22(4):286–291.
  • Beltrán-Miranda CP, Khan A, Jaloma-Cruz AR, Laffan MA. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005;11(4):326–334.
  • Pike GN, Cumming AM, Thachil J, Hay CRM, Burthem J, Bolton-Maggs PHB. Evaluation of the use of global haemostasis assays to monitor treatment in factor XI deficiency. Haemophilia 2017;23(2):273–283.
  • Schols SEM, Lancé MD, Feijge M a. H, Damoiseaux J, Marcus MA, Hamulyák K, Ten Cate H, Heemskerk JW, van Pampus EC. Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery. Thromb Haemost 2010;103(2):318–328.
  • Boeer K, Cuznetov L, Loesche W. Thrombin generation as marker to estimate thrombosis risk in patients with abnormal test results in lupus anticoagulant routine diagnostics. Thromb J 2013;11:24.
  • Zuily S, Regnault V, Guillemin F, Kaminsky P, Rat A-C, Lecompte T, Wahl D. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study. Thromb Res 2013;132(1):1–7.
  • Campo G, Pavasini R, Pollina A, Fileti L, Marchesini J, Tebaldi M, Ferrari R. Thrombin generation assay: a new tool to predict and optimize clinical outcome in cardiovascular patients? Blood Coagul Fibrinolysis 2012;23(8):680–687.
  • Ten Cate H, Hemker HC. Thrombin Generation and Atherothrombosis: What Does the Evidence Indicate? J Am Heart Assoc 2016;8;5(8).
  • Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Béguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003;33(1):4–15.
  • Regnault V, Hemker HC, Wahl D, Lecompte T. Phenotyping the haemostatic system by thrombography–potential for the estimation of thrombotic risk. Thromb Res 2004; 114 (5–6): 539–545.
  • Altman R, Scazziota AS, Herrera M de L, Gonzalez C. Thrombin generation by activated factor VII on platelet activated by different agonists. Extending the cell-based model of hemostasis. Thromb J 2006;4:5.
  • Ignjatovic V, Greenway A, Summerhayes R, Monagle P. Thrombin generation: the functional role of alpha-2-macroglobulin and influence of developmental haemostasis. Br J Haematol 2007;138(3):366–368.
  • Kremers RMW, Wagenvoord RJ, Hemker HC. The effect of fibrin(ogen) on thrombin generation and decay. Thromb Haemost 2014;112(3):486–494.
  • Camire RM, Pollak ES, Kaushansky K, Tracy PB. Secretable human platelet-derived factor V originates from the plasma pool. Blood 1998;92(9):3035–3041.
  • Sadler JE. von Willebrand factor. J Biol Chem 1991;266(34):22777–22780.
  • Rugeri L, Beguin S, Hemker C, Bordet J-C, Fleury R, Chatard B, Negrier C, Dargaud Y. Thrombin-generating capacity in patients with von Willebrand’s disease. Haematologica 2007;92(12):1639–1646.
  • Broos K, Feys HB, De Meyer SF, Vanhoorelbeke K, Deckmyn H. Platelets at work in primary hemostasis. Blood Rev 2011;25(4):155–167.
  • Ohlmann P, Eckly A, Freund M, Cazenave JP, Offermanns S, Gachet C. ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq. Blood 2000;96(6):2134–2139.
  • Oury C, Toth-Zsamboki E, Vermylen J, Hoylaerts MF. P2X(1)-mediated activation of extracellular signal-regulated kinase 2 contributes to platelet secretion and aggregation induced by collagen. Blood 2002;100(7):2499–24505.
  • Miszta A, Pelkmans L, Lindhout T, Krishnamoorthy G, de Groot PG, Hemker CH, Heemskerk JW, Kelchtermans H, de Laat B. Thrombin-dependent Incorporation of von Willebrand Factor into a Fibrin Network. J Biol Chem 2014;289(52):35979–86.
  • Mammadova-Bach E, Ollivier V, Loyau S, Schaff M, Dumont B, Favier R, Freyburger G, Latger-Cannard V, Nieswandt B, Gachet C, Mangin PH, Jandrot-Perrus M. Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. Blood 2015;126(5):683–691.
  • van der Meijden PEJ, Feijge MAH, Giesen PLA, Huijberts M, van Raak LPM, Heemskerk JWM. Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. Thromb Haemost 2005;93(6):1128–1136.
  • Tocchetti EV, Flower RL, Lloyd JV. Assessment of in vitro-generated platelet microparticles using a modified flow cytometric strategy. Thromb Res;1;103(1):47–55.
  • Zwaal RFA, Comfurius P, Bevers EM. Scott syndrome, a bleeding disorder caused by defective scrambling of membrane phospholipids. Biochim Biophys Acta 2004; 1636 (2–3): 119–128.
  • Percy CL, Macartney N, Pollard B, Rayment R, Collins PW. Laboratory monitoring of Scott Syndrome. Br J Haematol 2010;149(6):803.
  • Kindler S, Siegemund T, Führer D, Petros S. Thrombin generation assay in a patient with acquired factor V inhibitor. J Thromb Haemost 2008;6(11):1985–1987.
  • Aronson I, Du Toit JM, Jacobs P. Grey platelet syndrome. Lancet 1994;344(8931):1233–1234.
  • Ninivaggi M, Apitz-Castro R, Dargaud Y, de Laat B, Hemker HC, Lindhout T. Whole-blood thrombin generation monitored with a calibrated automated thrombogram-based assay. Clin Chem 201;58(8):1252–1259.
  • Kelchtermans H, Pelkmans L, Bouwhuis A, Schurgers E, Lindhout T, Huskens D, Miszta A, Hemcker HC, Lancé MD, de Laat B. Simultaneous measurement of thrombin generation and fibrin formation in whole blood under flow conditions. Thromb Haemost 2016;116(1):134–145.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.